CD25, CD27, CD30 and CD40 are receptors for IL-2, CD70, CD153 and CD154, respectively, which provide important signaling for both B- and T-cell immune responses. We therefore examined the sera of patients with Waldenstrom’s macroglobulinemia (WM), a B-cell disorder characterized by excess IgM secreting bone marrow lymphoplasmacytic cells (LPC) for the presence of soluble CD25, CD27, CD30, CD40, IL-2, CD153, and CD154. Sera were from patients with active disease and off-therapy. Sera from healthy age matched donors (HD) was used for controls. The results of these studies were as follows:

WM ELISA ResultsHD ELISA Results
p-valuen=medianrangen=medianrange
sCD25 pg/ml 2.647x10−6 41 3418.99 3–19756.2 20 573.6 184.96–891.03 
IL-2 pg/ml 0.72385 41 22.96 3–76.83 20 11.07 5.64–64.7 
sCD27 U/ml 2.4727x10−7 26 7.45 0–19.42 10 0–2.78 
sCD70 ND ND ND ND ND ND ND 
sCD30 U/ml 0.00088 25 89.25 0–550.81 15 39.12 0–135.25 
sCD153 ng/ml 0.68388 25 8.18 0–43.8 15 5.65 0–24.82 
sCD40 pg/ml 0.02484 25 101.39 11.76–584.99 11 50.73 0–150.5 
sCD154 pg/ml 0.81317 55 949.58 92–4973.16 17 1078.03 351.88–2323.38 
WM ELISA ResultsHD ELISA Results
p-valuen=medianrangen=medianrange
sCD25 pg/ml 2.647x10−6 41 3418.99 3–19756.2 20 573.6 184.96–891.03 
IL-2 pg/ml 0.72385 41 22.96 3–76.83 20 11.07 5.64–64.7 
sCD27 U/ml 2.4727x10−7 26 7.45 0–19.42 10 0–2.78 
sCD70 ND ND ND ND ND ND ND 
sCD30 U/ml 0.00088 25 89.25 0–550.81 15 39.12 0–135.25 
sCD153 ng/ml 0.68388 25 8.18 0–43.8 15 5.65 0–24.82 
sCD40 pg/ml 0.02484 25 101.39 11.76–584.99 11 50.73 0–150.5 
sCD154 pg/ml 0.81317 55 949.58 92–4973.16 17 1078.03 351.88–2323.38 

Considering our recent studies demonstrating a role for mast cells (MC) in supporting WM cell growth (JCO 2004 22:571S), we examined bone marrow LPC along with MC from WM patients for expression of CD25, CD27 and CD40 and/or their ligands by flow cytometry and RT-PCR analysis. The results of these studies are as follows:

Flow CytometryRT-PCR
WMMCWMMC
CD25 4/10 (40%) 2/7 (29%) 7/9 (78%) 7/15 (47%) 
IL-2 ND ND ND ND 
CD27 5/12 (42%) 2/8 (25%) 7/7 (100%) 4/7 (57%) 
CD70 6/6 (100%) 10/11 (91%) 7/7 (100%) 2/7 (29%) 
CD30 1/21 (4.7%) ND ND ND 
CD153 3/7 (43%) 12/13 (92%) 2/2 (100%) 9/11 (82%) 
CD40 25/30 (83%) ND ND ND 
CD154 2/3 (67%) 9/13 (69%) 7/9 (78%) ND 
Flow CytometryRT-PCR
WMMCWMMC
CD25 4/10 (40%) 2/7 (29%) 7/9 (78%) 7/15 (47%) 
IL-2 ND ND ND ND 
CD27 5/12 (42%) 2/8 (25%) 7/7 (100%) 4/7 (57%) 
CD70 6/6 (100%) 10/11 (91%) 7/7 (100%) 2/7 (29%) 
CD30 1/21 (4.7%) ND ND ND 
CD153 3/7 (43%) 12/13 (92%) 2/2 (100%) 9/11 (82%) 
CD40 25/30 (83%) ND ND ND 
CD154 2/3 (67%) 9/13 (69%) 7/9 (78%) ND 

The above studies demonstrate high levels of circulating immunoregulatory receptors, and expression of these receptors and/or their ligands on WM tumor and mast cells. Studies addressing their role in immune dysregulation in WM are underway.

Author notes

Corresponding author